ASLAN Pharmaceuticals Reports Publication Highlighting Unique Mechanism of Action in the Treatment of Atopic Dermatitis
| ASLNDelisted Stock | USD 0.60 0.03 4.76% |
About 62% of Aslan Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Aslan Pharmaceuticals suggests that many traders are alarmed regarding Aslan Pharmaceuticals' prospects. Aslan Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Aslan Pharmaceuticals. Many technical investors use Aslan Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Aslan |
ASLAN Pharmaceuticals Reports Publication Highlighting Unique Mechanism of Action in the Treatment of Atopic Dermatitis
Read at investing.com
 |
Aslan Pharmaceuticals Fundamental Analysis
We analyze Aslan Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Aslan Pharmaceuticals is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Aslan Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aslan Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aslan Pharmaceuticals Related Equities
| ANTX | AN2 Therapeutics | 21.90 | ||||
| GLUE | Monte Rosa | 13.72 | ||||
| LYRA | Lyra Therapeutics | 10.53 | ||||
| IOBT | IO Biotech | 4.71 | ||||
| CMPX | Compass Therapeutics | 4.49 | ||||
| CTMX | CytomX Therapeutics | 3.92 | ||||
| CGEM | Cullinan Oncology | 2.75 | ||||
| ADAG | Adagene | 1.30 | ||||
| ASMB | Assembly Biosciences | 1.25 | ||||
| AGIO | Agios Pharm | 1.24 | ||||
| ACHL | Achilles Therapeutics | 0.93 | ||||
| ACRV | Acrivon Therapeutics, | 0.80 | ||||
| ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
| AVTE | Aerovate Therapeutics | 0.38 | ||||
| IVA | Inventiva | 1.12 | ||||
| GPCR | Structure Therapeutics | 1.78 | ||||
| ERAS | Erasca | 2.05 | ||||
| MLYS | Mineralys Therapeutics, | 2.59 | ||||
| NAMS | NewAmsterdam Pharma | 4.57 | ||||
| TIL | Instil Bio | 9.39 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |